title: Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation.
abstract: BACKGROUND
  In patients with atrial fibrillation (AF), the risk of thromboembolic events (TEs) is variable and is influenced by the presence and number of comorbid conditions. The effect of percutaneous left atrial radiofrequency ablation (LARFA) of AF on the risk of TEs is unclear.
  
  
  RESULTS
  LARFA was performed in 755 consecutive patients with paroxysmal (n = 490) or chronic (n = 265) AF. Four hundred eleven patients (56%) had > or = 1 risk factor for stroke. All patients were anticoagulated with warfarin for > or = 3 months after LARFA. A TE occurred in 7 patients (0.9%) within 2 weeks of LARFA. A late TE occurred 6 to 10 months after ablation in 2 patients (0.2%), 1 of whom still had AF, despite therapeutic anticoagulation in both. Among 522 patients who remained in sinus rhythm after LARFA, warfarin was discontinued in 79% of 256 patients without risk factors and in 68% of 266 patients with > or = 1 risk factor. Patients older than 65 years or with a history of stroke were more likely to remain anticoagulated despite a successful outcome from LARFA. None of the patients in whom anticoagulation was discontinued had a TE during 25 +/- 8 months of follow-up.
  
  
  CONCLUSIONS
  The risk of a TE after LARFA is 1.1%, with most events occurring within 2 weeks after the procedure. Discontinuation of anticoagulant therapy appears to be safe after successful LARFA, both in patients without risk factors for stroke and in patients with risk factors other than age > 65 years and history of stroke. Sufficient safety data are as yet unavailable to support discontinuation of anticoagulation in patients older than 65 years or with a history of stroke.
authors.affiliation: Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA. oralh@umich.edu
authors.forename: Hakan
authors.initials: H
authors.lastname: Oral
authors.forename: Aman
authors.initials: A
authors.lastname: Chugh
authors.forename: Mehmet
authors.initials: M
authors.lastname: Ozaydin
authors.forename: Eric
authors.initials: E
authors.lastname: Good
authors.forename: Jackie
authors.initials: J
authors.lastname: Fortino
authors.forename: Sundar
authors.initials: S
authors.lastname: Sankaran
authors.forename: Scott
authors.initials: S
authors.lastname: Reich
authors.forename: Petar
authors.initials: P
authors.lastname: Igic
authors.forename: Darryl
authors.initials: D
authors.lastname: Elmouchi
authors.forename: David
authors.initials: D
authors.lastname: Tschopp
authors.forename: Alan
authors.initials: A
authors.lastname: Wimmer
authors.forename: Sujoya
authors.initials: S
authors.lastname: Dey
authors.forename: Thomas
authors.initials: T
authors.lastname: Crawford
authors.forename: Frank
authors.initials: F
authors.lastname: Pelosi
authors.forename: Krit
authors.initials: K
authors.lastname: Jongnarangsin
authors.forename: Frank
authors.initials: F
authors.lastname: Bogun
authors.forename: Fred
authors.initials: F
authors.lastname: Morady
mesh_terms: D000368:Aged; D001281:Atrial Fibrillation / Q000628:therapy*; D017115:Catheter Ablation / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D020521:Stroke / Q000453:epidemiology; D013923:Thromboembolism / Q000453:epidemiology*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D006493:Heparin